





Investor Presentation FY 2021-22

19th May 2022





Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents obtained by competitors. Challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.

Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.

You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.

The Company does not undertake any obligation to update forward-looking statements to reflect new information, future events, or otherwise after the date thereof.



Strategic Vision: A Global Pharma Company Focused on our Core Growth Platforms



India Region	Complex Gx Platforms	Global Developed Gx market footprint		
Achieving substantially above market growth	Substantial and scaled product platforms	Operational efficiency from Global presence		
Organic and in-organic growth, in our therapeutic areas and beyond, positioning us as the partner of choice for innovative pharmacos	Purposefully scaling our Inhalation, Injectables and Biosimilars across our footprint of Global businesses	Building operating leverage in CAPEX and R&D across markets with similar regulator regimes (i.e., US, UK, Europe, Canada and Australia)		

Top-decile Delivery of On-time Launches

Continuous Improvement Culture

Best in Class Global Quality

Industry trends



Price erosion has become business as usual for US Gx



Pressure has increased from both competition and purchasing groups

 YoY price decline of 7% in January, accelerated to 16% in February Global Inflationary Head Winds



Risk of high input prices to API/KSM pricing and utility costs

- FY23 margins likely challenged across industry from higher input costs
- Discontinuations likely high due to compressed industry margins

Need for low competition launches



Excellence in R&D more important than ever to driving top-line

 Due to erosion, the only proven path to growth is exclusive or otherwise low competition launches India growth to remain strong



Growth likely to revert to historical range of 10-12%


- High growth potential, but substantial hurdle to grow beyond market
- Industry M&A and diversification seen increasing in FY23

FDA resumes world-wide site inspections



Pipeline products stuck due to WLs

 With resumption of inspections by the US FDA, pipeline from Indian sites stuck due to warning letters could become available







Q4 FY2022 Snapshot



Sales (INR mn, YoY Growth)





Important developments

Commercial

- Lupin Completes Acquisition of Brands from Anglo-French
- Completed Southern Cross acquisition in Australia
- Lupin and Yabao Announce Strategic Partnership in China
- Lupin and Axantia Enter into a License, Supply and Technology Sharing Agreement for Pegfilgrastim in the Middle East and North Africa

Pipeline

- Received US FDA approval for :
 - Sildenafil for Oral Suspension
 - Vigabatrin for Oral Solution USP
 - Arformoterol Tartrate Inhalation Solution

Regulatory

• US FDA inspected Tarapur facility



North America





US Generics: An established leader¹

Managing our transition to Complex Generics


<u>44</u>	<u>22.6%</u>	<u>113</u>		US quar	terly sales	(\$ mn)	
Number of products Market leader	Albuterol Gx Market share	Number of Products Top 3 by Market Share	195	172	184	202	181
<u>3rd</u>	<u>160</u>	<u>196</u>					
Largest in the US (by prescriptions ¹)	Filings pending approval (cumulative)	DMF filings (cumulative)	Q4 FY21	Q1 FY22	Q2 FY22	Q3 FY22	Q4 FY22

• Launched 2 products in Q4 in US (gTaytulla and gRenagel) bringing the total marketed generic products to 166

• Current pipeline includes 53 FTFs incl. 21 exclusive FTF awaiting USFDA approval



Q4 growth at 5% YoY; domestic formulations grew 13.3% YoY with contribution from key therapy areas



India Quarterly Sales (INR mn)

Strong Portfolio						
	BRANDS	RANK (MAT MAR'22)				
	GLUCONORM-G	44				
3 in Top 100	HUMINSULIN	85				
•	BUDAMATE	96				
	ONDERO	215				
8 in Top 300	IVABRAD	229				
	GIBTULIO	231				
	TONACT	265				
	AJADUO	269				

Lupin continues to outpace industry growth in Chronic

	CAGR MAT	Mar'18–'22	Lupir	n Rank ¹
Therapy	Market	Lupin	MAT Mar'18	MAT Mar'22
Acute	11%	6%	12	15
Chronic	12%	14%	4	4
Cardiac	12%	14%	3	3
Anti-diabetics	11%	16%	4	3
Respiratory	14%	15%	3	2

- 6th Rank in IPM; 65% Chronic contribution
- For Lupin Respiratory & Gynae registered a double-digit growth in Q4 FY22
- Two therapies- Cardiac & Anti Diabetics are above INR 1,000 Crore sales
- New divisions launched: MindNext (CNS), Lupin Inspire (Diabetes) Maxter Neo (Anti-infective)

Other Markets Germany: EUR 8.4 mn sales in Q4 FY22 ٠ EU5 Developed Tempil [®] & Mens Health Portfolio have contributed to double-digit YoY growth ۲ 4th largest generics player¹ Australia Growth of 30% against industry growth of 7.5%¹ 4th largest Rx generics player²; Market leader in CVS space South Africa Emerging markets ZAR 426 mn sales in Q4 FY22 BRL 64 mn sales in Q4 FY22 (up 8% YoY); Brazil In our reference market, MedQuimica ranks #6 in units and #14 in Values MXN 183 mn sales in Q4 FY22; (growth of 19% YoY) Mexico Market Leader in Ophthalmology (#2 in units and #5 in values) with a national footprint ۲ API + Global API revenues declined 14% YoY in Q4 FY22 Institutional Continued leadership in anti-TB Institutional business



P&L Highlights- Q4 FY 2022



Amount in INR mn	Q4FY22	% of Sales	Q3FY22	% of Sales	QoQ Growth	Q4FY21	% of Sales	YoY Growth
Sales	38,645	100.0%	40,875	100.0%	-5.5%	37,593	100.0%	2.8%
Other operating income	185	0.5%	734	1.8%	-74.8%	238	0.6%	-22.3%
Total revenue	38,830	100.5%	41,609	101.8%	-6.7%	37,831	100.6%	2.6%
Gross Profit (excl. other operating income)	22,323	57.8%	23,929	58.5%	-6.7%	24,417	65.0%	-8.6%
EBITDA ¹	2,823	7.3%	4,039	9.9%	-30.1%	7,657	20.4%	-63.1%
PBT before exceptional item ^{1/2}	-864	-2.2%	1,671	4.1%		5,182	13.8%	
Exceptional item	-12	0.0%	0	0.0%		0.0%	0.0%	
PBT after exceptional item	-852	-2.2%	1,671	4.1%		5,182	13.8%	
Profit after Tax	-5,119	-13.2%	5,491	13.4%		4,642	12.3%	(
Profit/(Loss) for the period	-5,180	-13.4%	5,455	13.3%		4,604	12.2%	

1. In Q3 FY22, other expenses include the impact of one-time expenses of INR 1,932 mn related to residual Metformin returns from retail and consumers not identified previously, and a provision for aged stock returns of Oseltamivir given lack of an active flu season for the past two years.

2. Depreciation & Amortization & impairment expense of Q4 FY22 includes INR 1,267 mn on account of impairment of Gavis IPs.



P&L Highlights - FY22




Amount in INR mn	FY2022	% of Sales	FY2021	% of Sales	YoY Growth
Sales	161,928	100.0%	149,270	100.0%	8.5%
Other operating income	2,127	1.3%	2,360	1.6%	-9.9%
Total revenue	164,055	101.3%	151,630	101.6%	8.2%
Gross Profit (excl. other operating income)	97,116	60.0%	95,648	64.1%	1.5%
EBITDA ¹	23,073	14.2%	27,032	18.1%	-14.6%
PBT before exceptional item ¹	12,135	7.5%	16,751	11.2%	
Exceptional item ^{2/3}	25,861	16.0%	0	0.0%	
PBT after exceptional item	-13,726	-8.5%	16,751	11.2%	
Profit after Tax	-15,097	-9.3%	12,266	8.2%	
Profit/(Loss) for the period	-15,280	-9.4%	12,165	8.1%	

1. In Q3 FY22, other expenses include the impact of one-time expenses of INR 1,932 mn related to residual Metformin returns from retail and consumers not identified previously, and a provision for aged stock returns of Oseltamivir given lack of an active flu season for the past two years.

2. In Q2 FY2022 we had created a provision of INR 18,795 mn [including INR 375 mn towards litigation and settlement related expenses] under Glumetza class actions. The amounts due to the two plantiffs group was settled in Q3. We had a small reversal on account of litigation expense in Q4 of INR 12 mn.

3. Q2 FY2022 includes impairment expense of INR 7,077 mn for Solosec® IP.

Key Financial Metrics





Complex Generics and Biosimilars Opportunity



Opportunities exist in products with barriers to entry


Generics market offers opportunities in


- First to market / first to file opportunities
- Complex dosage forms like injectables, inhalation

With several biologics going off-patent, biosimilars have a long way to go with new launches and incremental penetration in US and EU

Complex categories market size (Brand + Generics) US\$ bn¹

Top Biologics Global Sales US\$ Bn²






Complex Generics and Biosimilars Opportunity

R&D investments focused toward complex generics and biosimilars

- Products in development target US\$ 70.7 bn of which complex categories account for ~85%
- Launches in key categories like Inhalation and biosimilars
- Several filings in each of the key categories underway



Evolving our Generic Portfolio and Pipeline

by timing of material contribution



Robust suite of depot, liposomal, peptide and iron injectable products in development



Scaling our early yet meaningful launches while advancing our robust pipeline of MDIs, DPIs, and SMIs

Biosimilars


Commercial momentum ex-US and evolving commercial capabilities in the US backed by exceptional R&D capabilities



Women's Health

Evolving internal LARC platforms and portfolio

Progress on US Inhalation Pipeline



Total Inhalation target market size of ~US\$ 22.4 bn



Progress on US Injectables Pipeline

Nanomi Pipeline



Product (Market Size) ¹	Formulation	Clinical Phase	Filing
Risperdal Consta			• Risperidone is at end of clinical phase
Depot 2		>	• Depot 2 and Depot 3 are at end of
Depot 3		>	formulation development stage

LRP Complex injectables Pipeline

Product Name (Market Size) ¹	API/RM/PM sourcing	Q1/Q2 status	Formulation and characterization	Validation	Registration batches	Clinical	Submission	
Product 1								
Product 2							Product 1 ha	
Product 3							• Product 2,3 clinical stage	
Product 4								

Complex Injectables market size ~US\$ 4.8 bn in depot; >US\$ 17.5 bn in other complex injectables

Progress on Biosimilar Pipeline

Molecule	Reference Product	Clone & Process Development	Pre- Clinical	Phase I	Phase III	Filing in US/EU/JP	US/EU/JP Approval & Launch	LUPIN
Etanercept	Enbrel®						Launched in JP/EU/I Filed: Canada/Austr Emerging Markets	ndia/Thailand alia and several other
Pegfilgrastim	Neulasta® (PFS & Onpro)						nder review by FDA and several in India. On-body-injector clini	
Ranibizumab	Lucentis®					Phase III (US/EU/Indi ration ongoing	a) ongoing. India MAA received	and Launch
Aflibercept	Eylea®				Toxicology stud	dies complete. IND in	preparation. Phase III to be init	iated shortly
Denosumab	Xgeva [®] , Prolia [®]			Тох	icology studies com	plete.		
Pertuzumab	Perjeta®			Toxicology s	tudies complete.			
Lupin0019			Clone Re	ady and Process fi	nalization ongoing.			
		Total Biosimilar	target ma	rket size of	[:] ~US\$ 36 br	1 ¹		









Optimization plan	1	Key initiatives	
ldle Time	Plant Work Force Optimization	Network Optimization	
Write-offs	Returns	Optimizing R&D investment	
Air Freight	FTS	Integrated Business Planning	
Low Margin SKUs			

Optimizing R&D investment



Invested INR 14 bn or 8.7% of sales on R&D in FY22at 7 R&D sites globally





Optimizing R&D spend

Targeting >US\$ 188 bn brand + generics sales, of which

- Filed products target US\$ 117.2 bn
- Products in development target US\$ 70.7 bn of which complex categories account for ~85%
- 53 First-to-Files (FTF) filings including 21 exclusive FTF opportunities targeting US\$ 5.9 bn

- Vinita Gupta ranks among 50 Most Powerful Women in Business by Fortune India
- Vinita Gupta, named among India's 20 Most Influential Women in Healthcare by BW Healthcare World
- Lupin wins two awards at the prestigious India Pharma Awards 2021
- "BEST Award" from Association of Talent Development 2022
- Lupin awarded 'Masters of Risk in Pharma & Healthcare' at India Risk Management Awards 7th Edition by CNBC-TV18
- Lupin named 'Best Researcher of the Year' at the ETHealthworld.com India Pharmaworld Awards
- Lupin Biotech wins 'Bioprocessing Excellence in South Asia' Award at the prestigious Asia Pacific Bioprocessing Excellence Awards 2022
- 3 sites rated 7 by ISRS (International Sustainability Rating System), the highest score in the pharma sector globally
- LupinLife's Be One wins the best packaging design, graphics and brand value add award at the India Packaging Awards 2021
- Taxation Team for wins FOUR awards at the ITR Asia-Pacific Tax Awards 2021 by the International Tax Review
- Sreeji Gopinathan, Chief Information Officer, Lupin makes it to the coveted Futuristic 100 CIOs list
- Greentech Energy Conservation Awards 2021 for Outstanding Achievement in Energy Conservation.
- Lupin's Ankleshwar facility won the Platinum Award for 7ACCA yield improvement project at 15th CII Six Sigma National Competition
- Lupin's Mandideep and Pithampur Facility Wins Gold At The National Awards for Manufacturing Competitiveness (NAMC)
- Lupin wins **Silver at the prestigious India Health and Wellness Summit & Awards** for Non-Communicable Disease (NCD) prevention campaign 'Shakti' for promoting awareness about heart diseases in women.
- Lupin's Team Synox has been recognized for **"Best Marketing Campaign of the Year"** at the ETHealthworld India Pharma World Awards, twice in a row.



India Pharma



Registered Office

Lupin Limited,

3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai 400 055, India. Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com





LupinWorld

